[go: up one dir, main page]

AU6972798A - Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog - Google Patents

Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Info

Publication number
AU6972798A
AU6972798A AU69727/98A AU6972798A AU6972798A AU 6972798 A AU6972798 A AU 6972798A AU 69727/98 A AU69727/98 A AU 69727/98A AU 6972798 A AU6972798 A AU 6972798A AU 6972798 A AU6972798 A AU 6972798A
Authority
AU
Australia
Prior art keywords
hiv
replication
inhibition
binding domain
peptide analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69727/98A
Inventor
Michael J. Leibowitz
Arnold B Rabson
Stanley Stein
Jihong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers Biomedical and Health Sciences
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of AU6972798A publication Critical patent/AU6972798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU69727/98A 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog Abandoned AU6972798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84444897A 1997-04-18 1997-04-18
US08844448 1997-04-18
PCT/US1998/007533 WO1998047913A2 (en) 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Publications (1)

Publication Number Publication Date
AU6972798A true AU6972798A (en) 1998-11-13

Family

ID=25292742

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69727/98A Abandoned AU6972798A (en) 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Country Status (2)

Country Link
AU (1) AU6972798A (en)
WO (1) WO1998047913A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8912698A (en) * 1997-08-19 1999-03-08 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030181367A1 (en) * 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
CA2386231C (en) * 1999-09-27 2010-09-14 Daniel J. O'mahony Membrane translocating peptide drug delivery system
US8183339B1 (en) * 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
ES2293977T3 (en) * 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHOD FOR USE.
US20030091640A1 (en) * 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US7803749B2 (en) 2002-01-09 2010-09-28 Xigen Sa Peptide inhibitors of MKK7 kinase binding to insulin binding proteins
US7364842B2 (en) * 2003-05-19 2008-04-29 Irm, Llc Methods of identifying modulators of human retrovirus replication
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
IT1397569B1 (en) 2009-12-10 2013-01-16 Icgeb PEPTIDES AND THEIR DERIVATIVES THAT INHIBIT THE EXTRACELLULAR RELEASE OF HIV-1 PROTEIN TAT AND THE REPLICATION OF HIV-1.
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
SG186706A1 (en) 2010-07-30 2013-02-28 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (en) 2010-10-01 2019-09-24 Moderna Therapeutics Inc manipulated nucleic acids and methods of use thereof.
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102014061B1 (en) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (en) 2011-12-16 2022-06-30 Modernatx Inc Modified mrna compositions
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
KR20160023669A (en) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2747762T3 (en) 2013-08-21 2020-03-11 Curevac Ag Respiratory syncytial virus (RSV) vaccine
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN114477459B (en) * 2022-01-17 2023-02-07 哈尔滨工业大学 Method for reducing antibiotic resistance genes in aquaculture wastewater

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0554284T3 (en) * 1990-10-24 1997-01-06 Allelix Biopharma Peptide-based inhibitors of HIV replication

Also Published As

Publication number Publication date
WO1998047913A3 (en) 1999-01-21
WO1998047913A2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
AU6972798A (en) Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
AU6479696A (en) Antisense inhibition of hepatitis b virus replication
AU3390297A (en) Uses of a chemokine receptor for inhibiting hiv-1 infection
AU6614696A (en) Inhibition of gene expression
AU2002246570A1 (en) Inhibition of restenosis using a dna-coated stent
AU6614596A (en) Inhibition of gene expression
AU2002229093A1 (en) Artificial tear composition containing a combination of three demulcents
AU8912698A (en) Inhibition of hiv-1 replication using d-amino acid peptides
AU4663297A (en) Inhibition of hiv replication using soluble tat peptide analogs
AU4248297A (en) Inhibition of viral replication
AU7807098A (en) Inhibition of hiv replication using a mutated transfer rna primer
AU6522599A (en) Use of a self-cleaving rna motif to modulate gene expression
AU1750497A (en) Compounds capable of inhibiting hiv-1 infection
BR9611838A (en) Compounds useful for inhibiting replication of HIV-1 AND HIV-1 mutants
AU7212694A (en) Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
AU2088399A (en) Brefeldin a derivatives
AU9336598A (en) A cigarette of ginkgo leaves
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
AU6962894A (en) Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU1327997A (en) Illuminated digital/analog wristwatch
AU2287595A (en) Class i peptide binding motifs
AU7666496A (en) Structure based design of inhibitors of hiv-1 reverse transcriptase
AU2095499A (en) Austenitic stainless steel including columbium
AU1764200A (en) Three dimensional structure of a sterile alpha motif domain
AUPN475295A0 (en) A toilet bowl

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase